Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“(R)-2HG competitively inhibited BCAT1, which is a cytosolic enzyme, with respect to 2OG over a physiologically-relevant range of 2OG concentrations”
From Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma (2018) · cites this paper as Koivunen et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“Though it is found at low levels in normal cells, D-2HG can accumulate to millimolar levels in cancer cells expressing mutant IDH. At these high concentrations, D-2HG can inhibit αKG-dependent dioxygenases, including enzymes involved in histone and DNA demethylation (Chowdhury et al., 2011; Janke et al., 2017; Koivunen et al., 2012; Xu et al., 2011).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Koivunen et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“Although HIF is typically viewed as an oncoprotein it can behave as a tumour suppressor in embryonic stem cell”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradatio”
BackgroundIto, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373 · cited 1×
“Human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 were produced in insect cells and purified as described earlie”
MethodAbsolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli
Bennett, B. D., Kimball, E. H., Gao, M., Osterhout, R., Van Dien, S. J., & Rabinowitz, J. D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.186 · Cited by 1,830 · cited 1×
“Studies in model organisms suggest that many metabolic enzymes are saturated in vivo with a mixture of substrate and competitive inhibitors and thus are sensitive to changes in substrate concentrations that are far above their nominal K m value”
BackgroundGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Nor are our data incompatible with the finding that HIF-1a protein levels are increased in IDH mutant tumours relative to normal brai”
ResultThe oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Cited by
Items 501–600 of 752
Wang, X., Cao, M., Chen, H., Ge, J., Suo, S., & Zhou, Y. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0037 · Cited by 20
CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma
Wang, S., Wu, J., Zhao, W., Li, M., & Li, S. (2023) · The FASEB Journal · doi:10.1096/fj.202201244rrrr · Cited by 16
Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia
Humphries, S., Bond, D. R., Germon, Z. P., Keely, S., Enjeti, A. K., Dun, M. D., & Lee, H. J. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01566-x · Cited by 16
“Thus, mutations in IDH have the potential to increase hypoxia signalling via loss of negative regulation [192, 193].”
BackgroundHypoxic regulation of extracellular vesicles: Implications for cancer therapy
Yoo, S., Choi, S., Kim, I., & Kim, I. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.034 · Cited by 15
ZEB1 expression is increased in IDH1-mutant lower-grade gliomas
Nesvick, C. L., Zhang, C., Edwards, N. A., Montgomery, B. K., Lee, M., Yang, C., Wang, H., Zhu, D., Heiss, J. D., Merrill, M. J., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2240-8 · Cited by 16
Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart
Karlstaedt, A., & Taegtmeyer, H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.06.008 · Cited by 15
Metabolic reprograming of cancer as a therapeutic target
Furukawa, T., Tabata, S., Minami, K., Yamamoto, M., Kawahara, K., & Tanimoto, A. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130301 · Cited by 16
Penn, A., McPherson, N. O., Fullston, T., Arman, B. M., & Zander‐Fox, D. (2023) · Reproduction · doi:10.1530/rep-22-0302 · Cited by 16
New Insights in AML Biology From Genomic Analysis
Perry, A. M., & Attar, E. C. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.08.005 · Cited by 16
van Lith, S. A. M., Navis, A. C., Lenting, K., Verrijp, K. N., Schepens, J. T. G., Hendriks, W. J. A. J., Schubert, N. A., Venselaar, H., Wevers, R. A., van Rooij, A., et al. (2016) · Scientific Reports · doi:10.1038/srep30486 · Cited by 15
“How this exactly contributes to oncogenesis is still an active field of investigation 15–17 .”
Hariharan, V., Denton, T. T., Paraszcszak, S., McEvoy, K., Jeitner, T. M., Krasnikov, B. F., & Cooper, A. J. L. (2017) · Biology · doi:10.3390/biology6020024 · Cited by 16
Anaplastic gliomas in adults: an update
Izquierdo, C., Joubert, B., & Ducray, F. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000409 · Cited by 16
Association between mutant IDHs and tumorigenesis in gliomas
Ohba, S., & Hirose, Y. (2018) · Medical Molecular Morphology · doi:10.1007/s00795-018-0189-8 · Cited by 15
15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma
Mannelli, M., Rapizzi, E., Fucci, R., Canu, L., Ercolino, T., Luconi, M., & Young, W. F. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0215 · Cited by 15
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Romanidou, O., Kotoula, V., & Fountzilas, G. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20101 · Cited by 15
Noonan, J., Jarzabek, M. A., Lincoln, F. A., Cavanagh, B., Pariag, A. R., Jurić, V., Young, L. S., Ligon, K. L., Jahns, H., Zheleva, D. I., et al. (2019) · Cancers · doi:10.3390/cancers11122005 · Cited by 15
“Human GBM neurosphere line, BT224-luc2 was donated by Dr Keith L Ligon of the Dana-Farber Cancer Institute, Boston, Massachusetts, USA; BT224-luc2 was derived from a patient at Brigham and Women’s Hospital undergoing surgery according to Institutional Review Board (IRB)-approved protocols, as previously described [56,…”
MethodSelf-citationIsocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
Gunn, K., & Losman, J.-A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041537 · Cited by 17
Self-citationThe oncometabolite L-2-hydroxyglutarate is a common product of dipteran larval development
Mahmoudzadeh, N. H., Fitt, A. J., Schwab, D. B., Martenis, W. E., Nease, L. M., Owings, C. G., Brinkley, G. J., Li, H., Karty, J. A., Sudarshan, S., et al. (2020) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2020.103493 · Cited by 15
2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS
Wahl, D. R., & Venneti, S. (2015) · Brain Pathology · doi:10.1111/bpa.12309 · Cited by 16
“Instead of blocking EGln1 activity, D-2-HG is thought to potentiate EglN1 activity, resulting in enhanced proliferation of immortalized human astrocytes in soft agar in an undefined manner (Figure 3) (44).”
BackgroundInfluentialInterplay between Epigenetics and Cellular Metabolism in Colorectal Cancer
Zhang, X., Dong, Z., & Cui, H. (2021) · Biomolecules · doi:10.3390/biom11101406 · Cited by 14
Clausing, M., William, D., Preussler, M., Biedermann, J., Grützmann, K., Richter, S., Buchholz, F., Temme, A., Schröck, E., & Klink, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105787 · Cited by 15
“2-HG is accepted as an oncometabolite, with many studies having been focused on oncogenic effects through the inhibition of α-KG dependent dioxygenases [10,11], such as hypoxia-inducible factor (HIF) hydroxylases and methylcytosine dioxygenase TET2, resulting in altered HIF activity and CpG island-methylator phenotype…”
BackgroundIDH1R132HMutation Increases U87 Glioma Cell Sensitivity to Radiation Therapy in Hypoxia
Wang, X.-W., Labussière, M., Valable, S., Pérès, E. A., Guillamo, J., Bernaudin, M., & Sanson, M. (2014) · BioMed Research International · doi:10.1155/2014/198697 · Cited by 14
“[11] showed that D-2HG (but not L-2HG) instead of being an inhibitor of EGLN (HIF prolyl 4hydroxylases) activity acts as a partial agonist of EGLN and promotes the degradation of HIF1α.”
BackgroundBackground Levels of Neomorphic 2-hydroxyglutarate Facilitate Proliferation of Primary Fibroblasts
Dvořák, A., Zelenka, J., Smolková, K., Vítek, L., & Ježek, P. (2017) · Physiological Research · doi:10.33549/physiolres.933249 · Cited by 14
“Also, a key component of hypoxia–inducible factor (HIF) regulation pathway, the prolyl hydroxylase domain-2 (PHD2/EglN1) enzyme has been found to be activated by R-2HG (Koivunen et al., 2012).”
BackgroundIDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC
Wang, J., Zhang, Z.-G., Ding, Z., Dong, W., Liang, H.-F., Chu, L., Zhang, B.-X., & Chen, X. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.04.056 · Cited by 14
Cienfuegos‐Pecina, E., Ibarra‐Rivera, T. R., Saucedo, A. L., Ramírez-Martínez, L. A., Esquivel-Figueroa, D., Domínguez-Vázquez, I., Alcántara-Solano, K., Moreno-Pena, D. P., Alarcón-Galván, G., Rodríguez-Rodríguez, D. R., et al. (2020) · PeerJ · doi:10.7717/peerj.9438 · Cited by 14
Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations
Berger, R. S., Ellmann, L., Reinders, J., Kreutz, M. P., Stempfl, T., Oefner, P. J., & Dettmer, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-43891-3 · Cited by 16
Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
Kitagawa, Y., Kobayashi, A., Cahill, D. P., Wakimoto, H., & Tanaka, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189102 · Cited by 13
Belle, R., Saraç, H., Salah, E., Bhushan, B., Szykowska, A., Roper, G., Tumber, A., Kriaučionis, S., Burgess-Brown, N., Schofield, C. J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01820 · Cited by 14
Krall, A. S., & Christofk, H. R. (2013) · Nature · doi:10.1038/496038a · Cited by 13
Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A
Horton, J. R., Liu, X., Wu, L., Zhang, K., Shanks, J. R., Zhang, X., Rai, G., Mott, B. T., Jansen, D. J., Kales, S. C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00261 · Cited by 13
Laitakari, A., Huttunen, R., Kuvaja, P., Hannuksela, P., Szabó, Z., Heikkilä, M. M., Kerkelä, R., Myllyharju, J., Dimova, E. Y., Serpi, R., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902331r · Cited by 13
Self-citationBiochemical Background in Mitochondria Affects 2HG Production by IDH2 and ADHFE1 in Breast Carcinoma
Špačková, J., Gotvaldová, K., Dvořák, A., Urbančoková, A., Pospíšilová, K., Větvička, D., Leguina‐Ruzzi, A., Tesařová, P., Vítek, L., Ježek, P., et al. (2021) · Cancers · doi:10.3390/cancers13071709 · Cited by 16
Formation of new lymphatic vessels in glioma: An immunohistochemical analysis
Meng, F., Liu, F., Liu, W., Li, L., & Jie, L. (2020) · Neuropathology · doi:10.1111/neup.12625 · Cited by 14
“However, other studies have indicated that HIF-1α expression is either not affected by an IDH mutation or even down-regulated.(25,26) Research has also shown that higher HIF-1α expression is associated with a higher degree of tumor malignancy.”
BackgroundMetabolic Rewiring in Adult-Type Diffuse Gliomas
Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087348 · Cited by 12
“However, unlike the initial observation, several studies have shown that 2-HG promotes prolyl hydroxylase activity, leading to low levels of the hypoxia-inducible factor subunit HIF-1alpha in IDH-mutant gliomas [79,80].”
BackgroundValvi, S., Fouladi, M., Fisher, M. J., & Gottardo, N. G. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1662414 · Cited by 12
“Other effects of elevated D-2-HG levels include promotion of angiogenesis via Vascular Endothelial Growth Factor Receptor VEGFR2 signaling, increased matrix metalloproteinase (MMP2) activity (Seok et al., 2019) and transformation of human astrocytes (Koivunen et al., 2012; Johannessen et al., 2016).”
Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal Cells
Worth, A. J., Gillespie, K. P., Mesaros, C., Guo, L., Basu, S. S., Snyder, N. W., & Blair, I. A. (2015) · Chemical Research in Toxicology · doi:10.1021/tx500535c · Cited by 12
Tiburcio, P. D. B., Xiao, B., Berg, S., Asper, S., Lyne, S. B., Zhang, Y., Zhu, X., Yan, H., & Huang, L. E. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1800-0 · Cited by 12
Self-citationMetabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy
Li, L., Eid, J. E., Paz, A. C., & Trent, J. C. (2017) · BioDrugs · doi:10.1007/s40259-017-0237-2 · Cited by 13
Metabolic functions of misunderstood D-2-hydroxyglutarate
Liu, Y., Kang, Z., Zhang, W., Ma, C., Xu, P., & Gao, C. (2024) · The Innovation Life · doi:10.59717/j.xinn-life.2024.100101 · Cited by 12
Yin, H., Zhang, X., Zhao, Z. F., Cao, C., Xu, M., Zhou, S., Xuan, T., Jin, Z., Han, L., Fan, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202503360 · Cited by 14
The role and regulatory mechanisms of the TCA cycle in early embryonic development
Lai, Y., Gao, X., Zhao, L., Liu, J., Gao, C., Yan, Q., Zeng, Y., Liao, Z., & Zhong, J. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1662431 · Cited by 12
“In the early stages of embryonic development, the low-oxygen environment in the mothers uterus inhibits SDH activity, leading to succinate accumulation (Koivunen et al., 2012).”
The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
Gruber, E., & Kats, L. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20230017 · Cited by 11
The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas
Cambruzzi, E. (2017) · Jornal Brasileiro de Patologia e Medicina Laboratorial · doi:10.5935/1676-2444.20170055 · Cited by 12
Wu, A., Gao, P., Wu, N., Shi, C., Huang, Z., Rong, C., Sun, Y., Sheng, L., Ouyang, G., & Mu, Q. (2021) · BMC Cancer · doi:10.1186/s12885-021-08303-8 · Cited by 11
Gregorio, E. D., Miolo, G., Saorin, A., Steffan, A., & Corona, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115574 · Cited by 13
Peng, S., Chen, H., Chen, L., Yang, G., Liu, J., Cheng, X., & Tang, Y. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00254 · Cited by 11
IDH-mutant gliomas in children and adolescents - from biology to clinical trials
Evans, L., Trinder, S. M., Dodgshun, A. J., Eisenstat, D. D., Whittle, J. R., Hansford, J. R., & Valvi, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1515538 · Cited by 11
“Additionally, D2-HG contributes to gliomagenesis by directly stimulating prolyl 4-hydroxylase activity, thereby decreasing hypoxia-inducible factor-a (HIF1 a ) activity, which enhances the proliferation of human astrocytes in vitro (2, 46).”
Mechanism analysis and targeted therapy of IDH gene mutation in glioma
Ma, X. (2025) · American Journal of Cancer Research · doi:10.62347/nsxc2205 · Cited by 12
Molecular classification of adult gliomas: recent advances and future perspectives
Barritault, M., Meyronet, D., & Ducray, F. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000482 · Cited by 10
Mechanisms of Metastasis and Cell Mobility – The Role of Metabolism
Gründker, C., Läsche, M., Hellinger, J. W., & Emons, G. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0805-9113 · Cited by 12
Hagiwara, A., Yao, J., Raymond, C., Cho, N. S., Everson, R. G., Patel, K. S., Morrow, D., Desousa, B. R., Mareninov, S., Chun, S., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102882 · Cited by 10
Wang, Z., Xiang, S., Zhou, C., & Xu, Q. (2023) · PeerJ · doi:10.7717/peerj.16125 · Cited by 11
“Moreover, the same is true of the occurrence and development of cancer (Xu et al., 2011; Chowdhury et al., 2011; Lu et al., 2012; Koivunen et al., 2012).”
Discovery of chirally dependent protein modifications by D- and L-2-hydroxyglutarates
Zhang, Z., Liu, Y.-K., Luo, Z., Wu, M., Evans, C. N., Qu, Z., Xue, F., Wang, Z., Stanciu, L., Zhang, Z., et al. (2026) · Nature Chemistry · doi:10.1038/s41557-026-02093-x · Cited by 9
“Overall, quantitative PTM analysis yielded 56 high-confidence D2HG-modified peptides in D2HG-accumulated cells (the criteria for high-confidence identification are detailed in Supplementary Note 2), showing strong overlap between IDH1-mutant RBE and H293T cells, and 130 high-confidence L2HG-modified peptides in L2HG-a…”
InfluentialOncometabolites as Regulators of DNA Damage Response and Repair
Gueble, S. E., & Bindra, R. S. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.09.004 · Cited by 10
Chen, M., Wang, Y., Dalal, R., Du, J., & Vollrath, D. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402384121 · Cited by 10
“Succinate and 2 - HG also inhibit 2 - ODGGs of the TET family of 5 - methylcytosine dioxygenases and the Jumonji family of lysine demethylases (47–50), which can modify epigenetic marks on DNA and histones, respectively, altering gene expression and perturbing differentiation (51, 52).”
BackgroundLuo, A., & Chen, Y. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00513 · Cited by 9
Oncogene brought into the loop
Grimmer, M., & Costello, J. (2015) · Nature · doi:10.1038/nature16330 · Cited by 10
Mao, M., & Leonardi, D. (2019) · Europe PMC (PubMed Central) · Cited by 14
Kang, S., Kwon, H. N., Kang, S., & Park, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.073 · Cited by 9
Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite
Berger, R. S., Wachsmuth, C. J., Waldhier, M. C., Renner, K., Thomas, S., Chaturvedi, A., Niller, H.-H., Bumes, E., Hau, P., Proescholdt, M. A., et al. (2021) · Cancers · doi:10.3390/cancers13081756 · Cited by 9
“The role of D-2-HG in prolyl hydroxylase (PHD) inhibition and, therefore, in HIF1α stabilization is still debated [12,14,15].”
BackgroundTsitlakidis, A., Tsingotjidou, A., Κritis, A., Cheva, A., Selviaridis, P., Aifantis, E. C., & Foroglou, N. (2021) · Cancers · doi:10.3390/cancers13184539 · Cited by 9
“Furthermore, although initial research linked 2-HG with the upregulation of hypoxia-induced factor 1α (HIF-1α) [52,53], a transcription factor activated by hypoxia and associated with tumor neovascularization, viability and growth [54], later studies questioned this link supporting the downregulation of HIF-1α by 2-HG…”
BackgroundProline hydroxylation linked to Akt activation
Voulgarelis, M., & Tsichlis, P. N. (2016) · Science · doi:10.1126/science.aah6254 · Cited by 9
Pfefer, T., Bessenyei, A. H., & O'Neill, L. A. J. (2026) · Immunology Letters · doi:10.1016/j.imlet.2026.107153 · Cited by 9
C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors
Viswanath, P., Li, Y., & Ronen, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_12 · Cited by 8
Zhao, Y., Yang, Y. L., Yang, R., Sun, C., Gao, X., Gu, X., Yuan, Y., Nie, Y.-T., Xu, S., Han, R., et al. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae002 · Cited by 9
“In addition, disturbing α -KG homeostasis can affect the activities of α -KG-dependent dioxygenases, such as Jumonji C-domain lysine demethylases (JmjC-KDMs) and ten-eleven translocation (TET) DNA cytosine-oxidizing enzymes [9–11].”
Fiorini, G., Marshall, S., Figg, W. D., Myers, W. K., Brewitz, L., & Schofield, C. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-75761-y · Cited by 8
Bund, C., Guergova-Kuras, M., Çiçek, A. E., Moussallieh, F., Dali‐Youcef, N., Piotto, M., Schneider, P., Heller, R., Entz‐Werlé, N., Lhermitte, B., et al. (2019) · Metabolomics · doi:10.1007/s11306-019-1522-5 · Cited by 8
Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma
Stahl, M. F., Epstein-Peterson, Z. D., & Intlekofer, A. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035477 · Cited by 13
Mitochondrial l-2-hydroxyglutarate is a physiological signalling metabolite
Chakrabarty, R. P., Vranken, J. G. V., Aoi, Y., Poor, T. A., McElroy, G. S., Vasan, K., Soliman, S. H. A., Iwanaszko, M., Grant, R. A., Howard, B. C., et al. (2026) · Nature · doi:10.1038/s41586-026-10564-x · Cited by 6
Optimizing homeostatic cell renewal in hierarchical tissues
Alvarado, C., Fider, N. A., Wearing, H. J., & Komarova, N. L. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005967 · Cited by 8
Yu, M., Ge, Y., Wang, Z., Zhang, Y., Hou, X., Chen, H., Chen, X., Ji, N., Li, X., & Shen, H. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04609-2 · Cited by 8
“IDH mutations can also increase the accumulation of 2HG, which is perceived to induce the degradation of HIF-1α, thus may reduce the formation of neovascularization[39].”
He, X., Liu, S., Lai, W., Yan, B., Liu, X., Jiang, Y., Liu, S., Chen, L., Shi, Y., & Tao, Y. (2016) · Chromatographia · doi:10.1007/s10337-016-3061-9 · Cited by 7
“A few methods can simultaneously determine TCA metabolites and 2HG in a single run, but only a few types of TCA cycle metabolites were determined [22].”
MethodTateishi, K., & Yamamoto, T. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.84543 · Cited by 10
“[33] demonstrated that IDH1 mutation attenuates HIF-1α through the activation of HIF prolyl 4-hydroxylase (EGLN), enhancing the proliferation and soft agar growth of NHA.”
BackgroundGenetic approaches to understand cellular responses to oxygen availability
Ortmann, B. M., & Nathan, J. A. (2021) · FEBS Journal · doi:10.1111/febs.16072 · Cited by 7
Wang, H., Yang, C., Huang, L., Li, Y., Bai, H., Zhao, R., Wei, Q., Wan, W., Chen, H., Zhang, J., et al. (2021) · Optics Express · doi:10.1364/oe.446884 · Cited by 7
Zhang, Y., Zhang, L., Fan, K., Gou, Y., Zang, Z., Ding, X., Yang, H., & Li, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.739631 · Cited by 9
Afsari, F., & McIntyre, T. M. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200050 · Cited by 8
Miyake, K., Baba, Y., Ishimoto, T., Hiyoshi, Y., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., Ogata, Y., Nagayama, M., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1229-x · Cited by 7
Chen, T., Yao, C., Chen, Y., Yuan, C., Lin, C., Hsu, Y.-C., Chuang, P., Kao, C., Li, Y.-H., Hou, H., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02193-1 · Cited by 8
“Phf6 is a chromatin-binding protein [50–52], and mutant Idh2 can lead to DNA hypermethylation [21, 22].”
BackgroundHypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome
Tchoghandjian, A., Koh, M. Y., Taïeb, D., Ganaha, S., Powis, G., Bialecki, E., Graziani, N., Figarella‐Branger, D., & Métellus, P. (2016) · Oncotarget · doi:10.18632/oncotarget.8046 · Cited by 6
“Interestingly, we found positive HIF-2α staining in 38.7% of cases which was uncorrelated to HIF-1α expression or IDH1/2 mutation status.”
BackgroundInfluentialThe Role of Epigenetic Modifier Mutations in Peripheral T-Cell Lymphomas
Țigu, A. B., & Bancos, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110563 · Cited by 9
Song, D., Fan, G., & Chang, M. (2024) · Cancers · doi:10.3390/cancers17010074 · Cited by 8
“IDH mutations also enhance the accumulation of 2-HG, which is believed to trigger the degradation of hypoxia-inducible factor 1 α (HIF-1 α ), potentially diminishing neovascularization [73].”
Comprehensive Analysis of 13C6 Glucose Fate in the Hypoxia-Tolerant Blind Mole Rat Skin Fibroblasts
Miskevich, D. A., Chaban, A., Dronina, M. A., Abramovich, I., Gottlieb, E., & Shams, I. (2021) · Metabolites · doi:10.3390/metabo11110734 · Cited by 6
“Although the role of 2HG in the inhibition/activation of PHD is controversial [47,48], our data suggest a possible involvement of 2HG in PHD inhibition.”
BackgroundLi, S., Shen, N., Wu, D., Zhang, J., Zhang, J., Jiang, J., & Zhu, W. (2022) · Current Medical Science · doi:10.1007/s11596-022-2563-y · Cited by 8
Approval of New Agents after Phase II Trials
Chabner, B. A. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.114 · Cited by 6
The role of micro-RNA in the regulation of signal pathways in gliomas
Kit, O. I., Vodolazhsky, D. I., Rostorguev, E. E., Porksheyan, D. H., & Panina, S. (2017) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20176306481 · Cited by 6
Hantel, A., Stock, W., & Kosuri, S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.017 · Cited by 8
Zhang, Y., Lv, W., Li, Q., Wang, Q., Ru, Y., Xiong, X., Yan, F., Pan, T., Lin, W. J., & Li, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10418 · Cited by 6
“By contrast, Koivunen et al (27) reported that r-2HG produced by mutant-idH1 enhanced the proliferation and soft agar growth of human astrocytes.”
ResultPennanen, M., Tynninen, O., Kytölä, S. I., Ellonen, P., Mustonen, H. K., Heiskanen, I., Haglund, C. H., & Arola, J. T. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa018 · Cited by 6
“The subsequent accumulation of the oncometabolite results in epigenetic dysregulation by inhibition of the α-ketoglutarate–dependent histone and DNA demethylases, and a block in cellular differentiation [6, 7].”
BackgroundQuantitative Analysis of Oncometabolite 2-Hydroxyglutarate
Yuan, B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51652-9_11 · Cited by 6
Tiwari, A. D., Guan, Y., Grabowski, D., Maciejewski, J. P., Jha, B. K., & Phillips, J. G. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116141 · Cited by 6
Mouse Models of Myeloid Malignancies
Basheer, F., & Vassiliou, G. S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035535 · Cited by 7
Immunotherapy and targeted therapy for high grade gliomas: current and future directions
Hsueh, B., Steuart, S. J., Odukoya, A. O., Prager, B. C., Kim, Y. J., Hill, C. M., Choi, B. D., & Dunn, G. P. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05315-3 · Cited by 5
“The most common point mutation in glioma, IDH R132H, is a gain-of-function mutation that leads to production of the metabolite 2-hydroxyglutarate, a competitive inhibitor of TET family proteins and histone demethylases [8, 9 ].”
Alberti, G., D’Amico, G., Augello, M. A., Cappello, F., Szychlinska, M. A., Bavisotto, C. C., & Scalia, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010373 · Cited by 5
“…reprogramming, known as the glioma CpG island methylator phenotype (G-CIMP), may influence the transcription of genes downstream of HIF-1 α [93] In contrast, reduced oxygen levels, typically of GBM, lead to an increase in intracellular acidification and NADH/NAD + concentration, which in…”
Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications
Fang, Y., Wang, X., Luo, K., Dakal, T. C., Bai, H., Xu, C., & Zhang, G. (2026) · MedComm · doi:10.1002/mco2.70732 · Cited by 6
“Additionally, D-2HG can activate the HIF prolyl 4-hydroxylases of the EGLN family (primarily EGLN1 and EGLN2), accelerating the hydroxylation and degradation of HIF-1 α , downregulating HIF activity, and thereby promoting tumorigenesis [ 69 ].”
Cienfuegos‐Pecina, E., Moreno-Pena, D. P., Torres-González, L., Rodríguez-Rodríguez, D. R., Villarreal, D. G., Mendoza-Hernández, O. H., Flores-Cantú, R. A., Samaniego-Sáenz, B. A., Alarcón-Galván, G., Muñoz-Espinosa, L. E., et al. (2021) · PeerJ · doi:10.7717/peerj.12426 · Cited by 5
Incorporating Targeted Therapy Into Neuro-Oncology Practice
Geurts, M., Blaquier, J. B., Wijnenga, M. M. J., Kamson, D. O., & de la Fuente, M. I. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473324 · Cited by 7
Structural basis of excitatory amino acid transporter 3 substrate recognition
Qiu, B., & Boudker, O. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2501627122 · Cited by 5
“R - 2HG is an oncometabolite that rewires the metabolism of cancer cells by inhibiting α-KG - dependent dioxygenases and changing epigenetic modification patterns ( 59 ).”
Heiblig, M., Khalife‐Hachem, S., Willekens, C., Micol, J., Paci, A., Penard‐Lacronique, V., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1831909 · Cited by 5
Xu, J., Xu, F., Liu, Z., Cui, Q., Zhang, K.-P., & Li, Z. (2022) · Medicine · doi:10.1097/md.0000000000029668 · Cited by 5
“[17,18] Nearly all IDH gene mutations are mutations of IDH1 (90%) or heterozygous mutations of IDH2 (3%)[19,20] IDH gene mutation is a phenomenon that occurs in the early development of gliomas and is currently considered the most important molecular biological marker Figure 1.”
Background
Metadata
- Authors
- Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., Travins, J., Weiss, S., Looper, R., Ligon, K. L., Verhaak, R. G. W., Yan, H., & Kaelin Jr, W. G.
- Affiliations
- University of Oulu (FI)
- Brigham and Women's Hospital (US)
- Duke University (US)
- Agios Pharmaceuticals (United States) (US)
- University of Calgary (CA)
- University of Utah (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 484-488
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656605
- OpenAlex
- W2142898716
- Cited by
- 727
- References
- 41
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 38 · 2023: 32 · 2022: 35 · 2021: 44 · 2020: 56 · 2019: 52 · 2018: 66 · 2017: 63 · 2016: 61 · 2015: 57 · 2014: 70 · 2013: 59 · 2012: 43
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA140316)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- R-enantiomer, IDH1 mutation, IDH2 mutation, hypoxia-inducible factor, glioma, astrocyte proliferation, oncometabolites, cancer metabolism, histone demethylation, DNA hypermethylation, CpG island methylator phenotype
- MeSH terms
- Astrocytes, Cell Line, Cell Transformation, Neoplastic, Enzyme Activation, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Nuclear Proteins, Oncogenes, Procollagen-Proline Dioxygenase, Cell Line, Tumor, Cell Proliferation, Dioxygenases, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.